Stock Track | I-Mab Soars 5.70% Pre-market on Board Appointments and R&D Committee Formation

Stock Track

Aug 25, 2025

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, saw its stock surge 5.70% in pre-market trading on Monday. The significant uptick comes on the heels of several key announcements that signal a strategic shift in the company's leadership and research focus.

The company revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This committee, which also includes Dr. Cao and CEO Dr. Sean Fu, is designed to accelerate innovation and long-term growth at I-Mab.

In addition to the board appointments, I-Mab announced the expansion of its Scientific Advisory Board with the addition of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These strategic moves are seen as bolstering I-Mab's expertise in R&D and immuno-oncology, particularly as the company progresses with its lead candidate, givastomig, a potential best-in-class bispecific antibody for gastric cancers. Investors appear to be reacting positively to these developments, viewing them as potential catalysts for the company's future growth and scientific advancements in the competitive biotech landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163136497"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163136497\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163136497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163136497","market":"sg","top_or_hot":-1,"title":"Stock Track | I-Mab Soars 5.70% Pre-market on Board Appointments and R&D Committee Formation","media":"Stock Track","content":"<p>I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, saw its stock surge 5.70% in pre-market trading on Monday. The significant uptick comes on the heels of several key announcements that signal a strategic shift in the company's leadership and research focus.</p>\n\n<p>The company revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This committee, which also includes Dr. Cao and CEO Dr. Sean Fu, is designed to accelerate innovation and long-term growth at I-Mab.</p>\n\n<p>In addition to the board appointments, I-Mab announced the expansion of its Scientific Advisory Board with the addition of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These strategic moves are seen as bolstering I-Mab's expertise in R&D and immuno-oncology, particularly as the company progresses with its lead candidate, givastomig, a potential best-in-class bispecific antibody for gastric cancers. Investors appear to be reacting positively to these developments, viewing them as potential catalysts for the company's future growth and scientific advancements in the competitive biotech landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | I-Mab Soars 5.70% Pre-market on Board Appointments and R&D Committee Formation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | I-Mab Soars 5.70% Pre-market on Board Appointments and R&D Committee Formation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-25 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, saw its stock surge 5.70% in pre-market trading on Monday. The significant uptick comes on the heels of several key announcements that signal a strategic shift in the company's leadership and research focus.</p>\n\n<p>The company revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This committee, which also includes Dr. Cao and CEO Dr. Sean Fu, is designed to accelerate innovation and long-term growth at I-Mab.</p>\n\n<p>In addition to the board appointments, I-Mab announced the expansion of its Scientific Advisory Board with the addition of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These strategic moves are seen as bolstering I-Mab's expertise in R&D and immuno-oncology, particularly as the company progresses with its lead candidate, givastomig, a potential best-in-class bispecific antibody for gastric cancers. Investors appear to be reacting positively to these developments, viewing them as potential catalysts for the company's future growth and scientific advancements in the competitive biotech landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1163136497","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163136497","pubTimestamp":1756124938,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, saw its stock surge 5.70% in pre-market trading on Monday. The significant uptick comes on the heels of several...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"个股追踪|天境生物盘前大涨5.70%董事会任命及研发委员会组建","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMAB":1},"content_text":"I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on immuno-oncology, saw its stock surge 5.70% in pre-market trading on Monday. The significant uptick comes on the heels of several key announcements that signal a strategic shift in the company's leadership and research focus.\nThe company revealed the appointment of three seasoned biotech executives to its Board of Directors: Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao. Dr. Lenz, a veteran research and development leader with experience at Neumora Therapeutics and Amgen, will chair the newly formed Research and Development Committee. This committee, which also includes Dr. Cao and CEO Dr. Sean Fu, is designed to accelerate innovation and long-term growth at I-Mab.\nIn addition to the board appointments, I-Mab announced the expansion of its Scientific Advisory Board with the addition of Dr. Ken Takeshita, a recognized biopharmaceutical executive and clinical development expert. These strategic moves are seen as bolstering I-Mab's expertise in R&D and immuno-oncology, particularly as the company progresses with its lead candidate, givastomig, a potential best-in-class bispecific antibody for gastric cancers. Investors appear to be reacting positively to these developments, viewing them as potential catalysts for the company's future growth and scientific advancements in the competitive biotech landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}